DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associated comorbidities such as pulmonary disease...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:METABOLISM-CLINICAL AND EXPERIMENTAL 2024-10, Vol.159
Hauptverfasser: Handelsman, Yehuda, Anderson, John E, Bakris, George L, Ballantyne, Christie M, Bhatt, Deepak L, Bloomgarden, Zachary T, Bozkurt, Biykem, Budoff, Matthew J, Butler, Javed, Cherney, David Z.I, DeFronzo, Ralph A, Del Prato, Stefano, Eckel, Robert H, Filippatos, Gerasimos, Fonarow, Gregg C, Fonseca, Vivian A, Garvey, W. Timothy, Giorgino, Francesco, Grant, Peter J, Green, Jennifer B, Greene, Stephen J, Groop, Per Henrik, Grunberger, George, Jastreboff, Ania M, Jellinger, Paul S, Khunti, Kamlesh, Klein, Samuel, Kosiborod, Mikhail N, Kushner, Pamela, Leiter, Lawrence A, Lepor, Norman E, Mantzoros, Christos S, Mathieu, Chantal, Mende, Christian W, Michos, Erin D, Morales, Javier, Plutzky, Jorge, Pratley, Richard E, Ray, Kausik K, Rossing, Peter, Sattar, Naveed, Schwarz, Peter E.H, Standl, Eberhard, Steg, P. Gabriel, Tokgozoglu, Lale, Tuomilehto, Jaakko, Umpierrez, Guillermo E, Valensi, Paul, Weir, Matthew R, Wilding, John, Wright Jr, Eugene E
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and associated comorbidities such as pulmonary diseases and metabolism dysfunction-associated steatotic liver disease and metabolism dysfunction-associated steatohepatitis (MASLD and MASH, respectively, formerly known as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [NAFLD and NASH]). Because cardiorenal and metabolic diseases share pathophysiologic pathways, two or more are often present in the same individual. Findings from recent outcome trials have demonstrated benefits of various treatments across a range of conditions, suggesting a need for practice recommendations that will guide clinicians to better manage complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. To meet this need, we formed an international volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM 2.0 Practice Recommendations, an updated and expanded revision of a previously published multispecialty consensus on the comprehensive management of persons living with DCRM. The recommendations are presented as 22 separate graphics covering the essentials of management to improve general health, control cardiorenal risk factors, and manage cardiorenal and metabolic comorbidities, leading to improved patient outcomes.
ISSN:0026-0495